Author | Year | Country | Study design | CFS/ME/SEID diagnostic criteria | Metabolite | Sample size | |||
---|---|---|---|---|---|---|---|---|---|
Sample | Targeted/untargeted | Analysis method | CFS/ME/SEID | HC | |||||
Germain et al. | 2020 [21] | USA | Case control | Fukuda | Plasma | Untargeted | Metabolon mass spectrometry | 26 F | 26F |
Germain et al. | 2018 [22] | USA | Case control | Fukuda | Plasma | Untargeted | Metabolon mass spectrometry | 32 F | 19 F |
Nagy-Szakal et al. | 2018 [29] | USA | Case control | Fukuda CCC | Plasma | Targeted and untargeted | Gas chromatography time-of-flight and liquid chromatography–tandem mass spectrometry | 26 | 49 |
Germain et al. | 2017 [23] | USA | Case control | Fukuda | Plasma | Untargeted | Q-exactive mass spectrometry | 17 F | 15 F |
Yamano et al. | 2016 [24] | Japan | Case control | Fukuda | Plasma | Untargeted | Capillary electrophoresis mass spectrometry | 41 F 5Â M | 41 F 6Â M |
Fluge et al. | 2016 [25] | Norway | Case control | CCC | Serum | Targeted | Gas chromatography–tandem mass spectrometry | 162 F 38 M | 67 F 35 M |
Naviaux et al. | 2016 [30] | USA | Case control | Fukuda CCC IOM | Plasma | Targeted | Triple quadrupole mass spectrometry | 23 F 22Â M | 21 F 18Â M |
Armstrong et al. | 2015 [26] | Australia | Case control | CCC | Serum Urine | Untargeted | Nuclear magnetic resonance spectrometry | 34 F | 25 F |
Armstrong et al. | 2012 [18] | Australia | Case control | CCC | Serum | Untargeted | Nuclear magnetic resonance spectrometry | 6 F 5Â M | 5 F 5Â M |
Jones et al. | 2005 [27] | United Kingdom | Case control | Fukuda Oxford | Plasma Urine | Targeted | Reversed phase chromatography | 19 F 11Â M | 19 F 11Â M |
McGregor et al. | 1996 [28] | Australia | Case control | Fukuda Oxford | Urine | Untargeted | Capillary gas chromatography–mass spectrometry | 16 F 4 M | 32 F 13 M |